Revolution Medicines (NASDAQ:RVMD) Releases Quarterly Earnings Results, Beats Estimates By $0.45 EPS

Revolution Medicines (NASDAQ:RVMD) issued its quarterly earnings results on Wednesday. The company reported ($1.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.35) by $0.45, FiscalAI reports. The firm had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million.

Here are the key takeaways from Revolution Medicines’ conference call:

• RASONQUE generated $197.6 million in net product revenue during roughly five weeks of U.S. commercialization, with more than 5,000 patients treated commercially and prescribing across academic and community settings. Management cautioned that early demand included finite expanded-access transitions and patients awaiting approval, so the initial results do not yet indicate the launch’s normalized trajectory.
• RASONQUE received a positive opinion from the European Medicines Agency’s CHMP, with a European Commission decision still pending, and NCCN added it as a preferred subsequent-therapy option in pancreatic cancer; the guideline also addresses settings beyond the FDA-approved indication. The company said more than 90% of U.S. pancreatic-cancer covered lives were represented by plans with reimbursed claims, although formal payer policies are still developing.
• Revolution advanced its pivotal pipeline: U.S. enrollment is complete in the first-line pancreatic cancer RASolute 303 study, global enrollment is expected to finish in the first half of 2027, and the RASONQUE–zoldonrasib doublet trial began dosing. It also initiated first-line lung cancer studies and is starting a global Phase III colorectal cancer trial, with BeOne funding and conducting that study.
• R&D and SG&A expenses rose to $417.1 million and $153.3 million, respectively, contributing to a quarterly net loss of $407.5 million. The company reiterated 2026 GAAP operating-expense guidance of $2.1 billion–$2.2 billion and expects expenses to increase in 2027 as it expands development and commercialization spending.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded up $5.47 during mid-day trading on Wednesday, reaching $199.70. The company had a trading volume of 2,528,849 shares, compared to its average volume of 2,784,084. The company has a 50-day moving average price of $198.21 and a two-hundred day moving average price of $156.90. The stock has a market cap of $42.80 billion, a PE ratio of -22.64 and a beta of 1.44. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines has a 1-year low of $58.00 and a 1-year high of $224.31.

Analyst Ratings Changes

Several analysts have recently weighed in on RVMD shares. Evercore restated an “outperform” rating and issued a $320.00 price objective on shares of Revolution Medicines in a report on Thursday, August 27th. TD Cowen reaffirmed a “buy” rating and set a $250.00 target price on shares of Revolution Medicines in a report on Wednesday, October 21st. William Blair started coverage on shares of Revolution Medicines in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Brookline Capital Markets started coverage on shares of Revolution Medicines in a report on Monday, September 28th. They issued a “buy” rating and a $318.00 price target for the company. Finally, UBS Group upped their price target on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a report on Friday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $242.90.

Insider Buying and Selling at Revolution Medicines

In related news, insider Alan Sandler sold 6,309 shares of the stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total value of $1,275,301.26. Following the completion of the transaction, the insider owned 52,559 shares in the company, valued at $10,624,276.26. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Margaret Horn sold 4,967 shares of Revolution Medicines stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the transaction, the chief operating officer directly owned 149,680 shares in the company, valued at $29,822,243.20. This represents a 3.21% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 290,991 shares of company stock valued at $59,422,765 over the last 90 days. 7.60% of the stock is owned by insiders.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.